Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 19/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL742925 | 0.84 | LTA4H (0.71) | LTA4HKCNH2 | |
| SCHEMBL1063026 | 0.83 | LTA4H (1.00) | LTA4HKCNH2 | |
| SCHEMBL2057465 | 0.82 | LTA4H (0.72) | LTA4HKCNH2 | |
| SCHEMBL1891207 | 0.82 | LTA4H (0.83) | LTA4HKCNH2 | |
| SCHEMBL12356865 | 0.82 | LTA4H (0.83) | LTA4HKCNH2 | |
| SCHEMBL1891054 | 0.81 | LTA4H (0.98) | LTA4HKCNH2 | |
| SCHEMBL1890177 | 0.80 | LTA4H (0.70) | LTA4HKCNH2 | |
| SCHEMBL1888042 | 0.80 | LTA4H (1.00) | LTA4HKCNH2 | |
| SCHEMBL1890064 | 0.80 | LTA4H (0.68) | LTA4HKCNH2 | |
| SCHEMBL1888142 | 0.79 | LTA4H (0.84) | LTA4HKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268646-B9 | THIAZOLOPYRIDIN-2-YLOXY-PHENYL AND THIAZOLOPYRAZIN-2-YLOXY-PHENYL AMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-19 | — | — | EP | claimed |
| EP-2268646-B1 | THIAZOLOPYRIDIN-2-YLOXY-PHENYL AND THIAZOLOPYRAZIN-2-YLOXY-PHENYL AMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-02 | — | — | EP | claimed |
| US-8357684-B2 | Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-22 | — | — | US | claimed |
| US-20110159563-A1 | Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICAL NV | 2011-06-30 | — | — | US | claimed |
| US-7939527-B2 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-10 | — | — | US | claimed |
| EP-2268646-A2 | THIAZOLOPYRIDIN-2-YLOXY-PHENYL AND THIAZOLOPYRAZIN-2-YLOXY-PHENYL AMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | Janssen Pharmaceutica, N.V. (BE) | 2011-01-05 | — | — | EP | claimed |
| WO-2009126806-A2 | THIAZOLOPYRIDIN-2-YLOXY-PHENYL AND THIAZOLOPYRAZIN-2-YLOXY-PHENYL AMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-15 | — | — | WO | claimed |
| US-20090258854-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-15 | — | — | US | claimed |
| US-11426399-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | ALKAHEST, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2022-07-21 | — | — | US | disclosed |
| US-11344542-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | ALKAHEST, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3793602-A1 | TREATMENT OF AGING-ASSOCIATED DISEASE WITH MODULATORS OF LEUKOTRIENE A4 HYDROLASE | Alkahest, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20200368220-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20190350917-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2019-11-21 | — | — | US | disclosed |
| US-7939527-B2 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-10 | — | — | US | disclosed |
| US-7939527-B2 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-10 | — | — | US | disclosed |
| WO-2009126806-A2 | THIAZOLOPYRIDIN-2-YLOXY-PHENYL AND THIAZOLOPYRAZIN-2-YLOXY-PHENYL AMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-15 | — | — | WO | disclosed |
| US-20090258854-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258854-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258854-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344542-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885KCNH2 3977/4885CYP2D6 2337/4885 |
| US-20190350917-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885KCNH2 3977/4885CYP2D6 2337/4885 |
| US-11426399-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885KCNH2 3977/4885CYP2D6 2337/4885 |
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885KCNH2 3977/4885CYP2D6 2337/4885 |
| US-20090258854-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | LTA4H, LTC4S, LTB4R2 | LTA4H 1/4885KCNH2 2499/4885CYP2D6 657/4885 |
| US-20110159563-A1 | Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | LTA4H, LTC4S, LTB4R2 | LTA4H 1/4885KCNH2 1523/4885CYP2D6 534/4885 |
| US-20200368220-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885KCNH2 3977/4885CYP2D6 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.